Exploring Methylene Blue and Its Derivatives in Alzheimer’s Treatment: A Comprehensive Review of Randomized Control Trials
This 2023 comprehensive review evaluates randomized clinical trials investigating methylene blue (MB) and its derivatives for Alzheimer’s disease (AD) treatment. MB, a thiophenazine dye with FDA approval for various conditions, can cross the blood-brain barrier, making it a candidate for central nervous system therapies. The review highlights MB’s potential benefits,